Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02

Url canonique :
Url courte ou permalien :

Molecular defects in cardiovascular disease, Softcover reprint of the original 1st ed. 2011

Langue : Anglais

Coordonnateurs : Dhalla Naranjan S., Nagano Makoto, Ostadal Bohuslav

Couverture de l’ouvrage Molecular defects in cardiovascular disease
Molecular Defects in Cardiovascular Disease provides an in-depth discussion of the molecular mechanisms underlying the genesis of cardiovascular defects and the implications this has on current and emerging targeted therapeutics.  Divided into three sections, this book covers the scientific foundations of our present understanding as well as the array of clinical manifestations and their treatment.  The first section covers Molecular Mechanisms of Heart Disease, with discussion of the development of cardiovascular dysfunction.  The remaining two sections provide a more clinical focus.  The second, Cardiac Hypertrophy and Heart Failure deals with metabolic derangements, Ca2+ handling, and subcellular remodeling.  It illustrates the wide variety of molecular defects which may serve as targets associated with the transition from cardiac hypertrophy to advanced heart failure.  The third section, Hypertension and Diabetes, provides molecular rationale for the pathogenesis of hypertension and diabetic cardiomyopathy, as well as highlighting the importance of hormones toward this end. A necessary resource for clinicians and researchers, this book elucidates the experimental basis of the practice of cardiology.  It is the culmination of our advances in the understanding of cardiovascular molecular biology and a blueprint for the efficacious use of targeted therapies.

A.  Molecular Mechanisms in Heart Disease


1.   Calcium overloading-induced oxidative stress-mediated cellular and subcellular remodeling

Y. Cheema, A.U. Shahbaz, S.K. Bhattacharya, R.A. Ahokas, Y.Sun, I.C. Gerling and K.T. Weber


2.   Intracellular MMP-2:  Role in normal and diseased hearts

N. Youssef and R. Schulz


3.   Control of the mesenchymal-derived cell phenotype by Ski and Meox2: A putative mechanism for post-developmental phenoconversion

R.H. Cunnington, J.T. Wigle, J.M. Douville, D.H. Freed, D. Schaafsma, S. O’Connor, S. Gupta, S.G. Rattan, A. Halayko and I.M.C. Dixon


4.   Elevated Na+/H+ exchanger expression and its role in myocardial disease

L. Fliegel


5.   Impact of perinatal chronic hypoxia on cardiac tolerance to acute ischemia

B. Ostadal, I. Ostadalova, F. Kolar, I. Netuka, O. Szarszoi,


6.   Stem cell, microRNA and redox cycling

P. Mukhopadhay, N. Gurusamy and D.K. Das


7.   Cardiac cell therapy: Present and future

D.K. Singla


B.  Cardiac Hypertophy and Heart Failure


8.   Macroscopic and microscopic aspects of cardiac dysfunction in congestive heart failure

      H.E.D.J. ter Keurs


9.   Cardiac dysfunction and metabolism: Unravelling the molecular cross-talk

V. Sharma and J.H. McNeill


10. Metabolic remodeling of the hypertrophied heart

J.M. Dai and M.F. Allard


11. Mechanisms for the regulation of phospholipase C gene expression in cardiac hypertrophy

P.S. Tappia


12. Molecular changes in fatty acid oxidation in the failing heart

J.S. Jaswal, W. Keung, W. Wang, J.R. Ussher and G.D. Lopaschuk


13. Cardiolipin metabolism in experimental and human heart failure

G.M. Hatch


14. Mechanisms underlying development of cardiomyocyte hypertrophy via Na-H exchange stimulation

M. Karmazyn


15. The structural basis of cardiac dysfunction in human heart failure

S. Hein, S. Kostin and J. Schaper


16. Hormonal mechanisms of cardiac remodeling in heart failure

A.P. Babick, V. Elimban and N.S. Dhalla


17. Modulators of remodeling after myocardial infarction

B.I. Jugdutt


18. Phosphodiesterase-5 inhibitors in protection against doxorubicin-induced cardiomyopathy

S. Koka and R.C. Kukreja


C.  Hypertension and Diabetes


19. Molecular basis of pulmonary hypertension in left heart failure

B. Raj, H.S. Pillai and C.C. Kartha


20. Modulation of Gi protein expression in hypertension: Molecular mechanisms

M.B. Anand-Srivastava


21. Vascular dysfunction in heart disease

R. Perrault and P. Zahradka


22. Cellular and molecular mechanisms associated with salicylate inhibition of intimal hyperplasia balloon catheter-induced vascular injury

S.N. Murthy, P.J. Kadowitz and D.B. McNamara


23. Involvement of growth factor receptor and non receptor protein tyrosine kinases in endothelin 1 and angiotensin II-induced signaling pathways in the cardiovascular system.

G. Vardatsikos and A.K. Srivastava


24. Sarco/endoplasmic reticulum Ca2+ pump damage by oxidative stress: Implications for Ca2+ entry

G. Akolkar and A.K. Grover


25. Obesity-hypertension: Leptin as the common link to cardiovascular and renal dysregulation

S. Kshatriya, H. Kozman, D. Siddiqui, L. Bhatta, K. Liu, A. Salah, T. Ford, R. Michiel, R. Carhart and D. Villarreal


26. Cardiorenal protection in diabetes mellitus

H. Vashistha, L.G. Meggs and A. Malhotra


27. Molecular mechanisms in the pathogenesis of diabetic cardiomyopathy

S. Chakrabarti

Outlines novel targets for the treatment of cardiovascular diseases

Elucidates the role of biochemical insults and metabolic derangements in altering gene expression

Provides an understanding of the molecular genesis of cardiovascular dysfunction

Date de parution :

Ouvrage de 382 p.

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 210,99 €

Ajouter au panier

Date de parution :

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 210,99 €

Ajouter au panier

Thèmes de Molecular defects in cardiovascular disease :

En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.